Lisa McKerracher of BioAxone BioSciences Joins Advisory Panel for Christopher Reeve Foundation

Lisa McKerracher, CEO of MBBP client BioAxone BioSciences, has accepted the role of Consortium Advisory Panelist for the Christopher & Dana Reeve Foundation. Dr. McKerracher will "direct the foundation's focus toward the identification, development, and translation of potential Spinal Cord Injury (SCI) therapies into the clinic." BioAxone BioSciences is a clinical-state biopharmaceutical company developing regenerative therapeutic …

Continue reading Lisa McKerracher of BioAxone BioSciences Joins Advisory Panel for Christopher Reeve Foundation

NIH/SBIR Grant Awarded to Firm Client BioAxone BioSciences for BA-1049 Inhibitor Research

The National Institutes of Health (NIH), Small Business Innovation Research (SBIR), and National Institute of Neurological Disorders and Stroke have awarded firm client BioAxone BioSciences, Inc. with a $1.5 million grant. The grant is for continued research for BioAxone's Rho Kinase 2 (ROCK2) inhibitor, BA-1049, a transformative drug to treat cerebral cavernous malformation, a serious …

Continue reading NIH/SBIR Grant Awarded to Firm Client BioAxone BioSciences for BA-1049 Inhibitor Research

BioAxone BioSciences Peer-Reviewed Research Article Published in Frontiers Journal Series

Firm client BioAxone BioSciences announced that its peer-reviewed research article on axon regeneration was published in Frontiers Journal Series, Frontiers in Molecular Neuroscience. The article "MAG, Myelin and Overcoming Growth Inhibition in the CNS" was written by BioAxone's CEO Lisa McKerracher, Ph.D. and Kenneth Rosen, Ph.D., VP of Research. Frontiers in Molecular Neuroscience publishes rigorously …

Continue reading BioAxone BioSciences Peer-Reviewed Research Article Published in Frontiers Journal Series